ClinicalTrials.gg
TerminatedNCT03519256CheckMate 9UTUpdated Jun 1, 2023Results posted

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

A Phase 2 interventional study of Nivolumab and BCG in Urinary Bladder Neoplasms, sponsored by Bristol-Myers Squibb. Terminated at 88 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-01.

Primary conditionNon-Muscle Invasive Bladder NeoplasmsRegistry: Urinary Bladder NeoplasmsReclassifiedWhy we changed it
Registry
Urinary Bladder Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Muscle Invasive Bladder Neoplasms
Why
  1. The study's title name Non-Muscle Invasive Bladder Neoplasms, a narrower term within Urinary Bladder Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
Insufficient Enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Enrollment
29th of 93
142 · median 55
Started
2018
with 4 others
Phase 2
20 of 114
8 open now
Registered
31st of 114
by date

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 29th largest by enrollment of the 93 interventional ones that give a count, is one of 5 that started in 2018, is one of 20 in phase 2, and was the 31st registered.

Non-Muscle Invasive Bladder Neoplasms

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 77 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.

03

Conditions studied

  • Urinary Bladder Neoplasms

Browse trials for

Keywords

  • Bladder Cancer
  • BCG-unresponsive
  • Nivolumab
  • Intravesical BCG
  • NMIBC
  • Non-Muscle Invasive
  • BMS-986205
  • CheckMate 9UT
04

In context

Non-Muscle Invasive Bladder Neoplasms Reclassified

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

This study's enrollment of 142 is above the median of 62 across 231 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Bladder Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologically demonstrated BCG-unresponsive, carcinoma in situ (CIS)-containing high-risk non-muscle-invasive bladder cancer (NMIBC) defined as CIS with or without papillary component
  • Participants must have CIS to be eligible.
  • Predominant histologic component (> 50%) must be urothelial (transitional cell) carcinoma
  • (ECOG) performance status 0-1

Exclusion criteria

Exclusion Criteria:

  • Sign of locally advanced disease or bladder cancer
  • Urothelial cancer (UC) in the upper genitourinary tract (kidneys, renal collecting systems, ureters) within 24 months of enrollment
  • Prior immuno-oncology therapy

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Nivolumab monotherapy

    Biological: Nivolumab

  • Experimental
    Nivolumab + BCG

    Biological: Nivolumab · Biological: BCG

  • Experimental
    Nivolumab + BMS-986205

    Biological: Nivolumab · Drug: BMS-986205

  • Experimental
    Nivolumab + BMS-986205 + BCG

    Biological: Nivolumab · Biological: BCG · Drug: BMS-986205

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • BiologicalBCG

    Specified dose on specified days

    Also known as: Bacillus Calumette-Guerin

  • Specified dose on specified days

07

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

  2. Number of Participants With Serious Adverse Events (SAEs)

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization. SAEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

  3. Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Treatment

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs leading to discontinuation are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

  4. Number of Participants Immune-Mediated Adverse Events (IMAEs)

    IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity IMAEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

  5. Number of Participants Who Died

    Number of participants who died.

    Time frame: From first dose to 100 days post last dose of study treatment (an average of 45 weeks up to approximately 74 weeks)

  6. Number of Participants With Specific Liver Laboratory Abnormalities

    On-treatment laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal.

    Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

  7. Number of Participants With Specific Thyroid Laboratory Abnormalities

    On-treatment laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal

    Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

  8. Number of Participants With Changes From Baseline Laboratory Values

    On-study laboratory parameters include hematology, chemistry, liver function, and renal function. On-study laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. On-study lab parameters are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: From baseline to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

  9. Number of Participants With Adverse Events (AEs) by Anti-Drug- Antibody (ADA) Status

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An Anti-drug antibody (ADA) is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are cross-reactive with the administered biologic drug. An ADA-positive participant has at least one ADA positive-sample relative to baseline at any time after initiation of treatment An ADA-negative participant doesn't not have an ADA-positive sample after the initiation of treatment.

    Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

  10. Number of Participants With Serious Adverse Events (SAEs) by Anti-Drug- Antibody (ADA) Status

    Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization. An Anti-drug antibody (ADA) is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are cross-reactive with the administered biologic drug. An ADA-positive participant has at least one ADA positive-sample relative to baseline at any time after initiation of treatment An ADA-negative participant doesn't not have an ADA-positive sample after the initiation of treatment.

    Time frame: From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)

08

Results

Posted Jun 1, 2023
Limitations and caveats
As of early April 2021, Study CA2099UT enrollment was significantly behind the projected target enrollment, (number of participants enrolled 142; target enrollment 480). Since the study would be unable to meet the scientific objectives within a projected timeline, a decision was made in May 2021 to close the study.

Participant flow

Participant flow — Overall Study
MilestoneArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Started16261710
Safety-lead in phase010010
Completed61523
Not completed1011157
Withdrew: Disease recurrence4452
Withdrew: Study drug toxicity0252
Withdrew: Adverse event unrelated to study drug0110
Withdrew: Participant request to discontinue study treatment0002
Withdrew: Other reasons0020
Withdrew: Disease progression6321
Withdrew: Lost to follow-up0100

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Number of Participants With Adverse Events (AEs)15261510
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization. SAEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Number of Participants With Serious Adverse Events (SAEs)2464
PrimaryNumber of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Treatment

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs leading to discontinuation are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Treatment
ParticipantsArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Treatment1487
PrimaryNumber of Participants Immune-Mediated Adverse Events (IMAEs)

IMAEs are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity IMAEs are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Reported as:
Count of participants · Participants
Number of Participants Immune-Mediated Adverse Events (IMAEs)
ParticipantsArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Number of Participants Immune-Mediated Adverse Events (IMAEs)11065
PrimaryNumber of Participants Who Died

Number of participants who died.

Time frame:
From first dose to 100 days post last dose of study treatment (an average of 45 weeks up to approximately 74 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Number of Participants Who Died0320
PrimaryNumber of Participants With Specific Liver Laboratory Abnormalities

On-treatment laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. ALT = Alanine Aminotransferase AST = Aspartate Aminotransferase ULN = Upper Limit of Normal.

Time frame:
From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Specific Liver Laboratory Abnormalities
ParticipantsArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
ALT OR AST > 3XULN0172
ALT OR AST> 5XULN0051
ALT OR AST> 10XULN0011
ALT OR AST > 20XULN0010
TOTAL BILIRUBIN > 2XULN0011
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 1 DAY0010
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>1.5XULN IN 30 DAYs0010
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY0010
ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30 DAYS0010
ALP>1.5XULN0210
PrimaryNumber of Participants With Specific Thyroid Laboratory Abnormalities

On-treatment laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal

Time frame:
From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Specific Thyroid Laboratory Abnormalities
ParticipantsArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
TSH > ULN5521
TSH > ULN WITH TSH <= ULN AT BASELINE4511
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN2120
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN2310
TSH > ULN WITH FT3/FT4 TEST MISSING2301
TSH < LLN2331
TSH <LLN WITH TSH >= LLN AT BASELINE2331
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN2111
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN1300
TSH < LLN WITH FT3/FT4 TEST MISSING0020
PrimaryNumber of Participants With Changes From Baseline Laboratory Values

On-study laboratory parameters include hematology, chemistry, liver function, and renal function. On-study laboratory evaluations are evaluations taken after the day (and time, if collected and not missing) of first dose of study treatment. For participants who are off study treatment, evaluations were within a safety window of 30 days after the last dose of study treatment. On-study lab parameters are reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
From baseline to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Changes From Baseline Laboratory Values
ParticipantsArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Hemoglobin1756
Platelet Count1111
Leukocytes, Local Lab0040
Lymphocytes (Absolute)0030
Lymphocytes (Absolute), Local Lab2725
Absolute Neutrophil Count0110
Alkaline Phosphatase (ALP), Local Lab0221
Aspartate Aminotransferase (AST), Local Lab35123
Alanine Aminotransferase (ALT), Local Lab410137
Bilirubin Total, Local Lab1253
Creatinine, Local Lab1835
Hypernatremia0342
Hyponatremia4343
Hyperkalemia0323
Hypokalemia2211
Hypercalcemia2403
Hypocalcemia0122
Hypermagnesemia3120
Hypomagnesemia1313
Hyperglycemia4131
Hypoglycemia0110
PrimaryNumber of Participants With Adverse Events (AEs) by Anti-Drug- Antibody (ADA) Status

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. An Anti-drug antibody (ADA) is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are cross-reactive with the administered biologic drug. An ADA-positive participant has at least one ADA positive-sample relative to baseline at any time after initiation of treatment An ADA-negative participant doesn't not have an ADA-positive sample after the initiation of treatment.

Time frame:
From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) by Anti-Drug- Antibody (ADA) Status
ParticipantsArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Nivolumab ADA Positive—11—
Nivolumab ADA Negative1121119
PrimaryNumber of Participants With Serious Adverse Events (SAEs) by Anti-Drug- Antibody (ADA) Status

Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening (an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) * Requires inpatient hospitalization or causes prolongation of existing hospitalization. An Anti-drug antibody (ADA) is defined as biologic drug-reactive antibody, including pre-existing host antibodies that are cross-reactive with the administered biologic drug. An ADA-positive participant has at least one ADA positive-sample relative to baseline at any time after initiation of treatment An ADA-negative participant doesn't not have an ADA-positive sample after the initiation of treatment.

Time frame:
From first dose to 30 days post last dose of study treatment (an average of 45 weeks up to approximately 64 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) by Anti-Drug- Antibody (ADA) Status
ParticipantsArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
Nivolumab ADA Positive0100
Nivolumab ADA Negative1344

Adverse events

Collected over Participants were assessed for All-Cause Mortality from the date of their randomization until study completion (assessed up to approximately 48 months). SAEs and Other AEs were assessed from first dose to 100 days after last dose of study therapy (an average of 45 weeks up to approximately 74 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Nivolumab0/16 (0%)4/16 (25%)15/16 (93.8%)
Arm B: Nivolumab Plus Intravesical BCG3/26 (11.5%)7/26 (26.9%)26/26 (100%)
Arm C: Nivolumab Plus BMS-9862052/17 (11.8%)7/17 (41.2%)15/17 (88.2%)
Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG0/10 (0%)5/10 (50%)10/10 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
HaematuriaRenal and urinary disorders0/160/260/172/10
Bladder cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/160/261/171/10
Retroperitoneal haemorrhageGastrointestinal disorders0/160/260/171/10
Bile duct stoneHepatobiliary disorders0/160/260/171/10
HyperglycaemiaMetabolism and nutrition disorders1/160/260/171/10
HyponatraemiaMetabolism and nutrition disorders0/160/260/171/10
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/160/261/171/10
HypotensionVascular disorders0/160/260/171/10
DiarrhoeaGastrointestinal disorders1/160/260/170/10
SepsisInfections and infestations1/160/260/170/10
Most frequent other events
Showing 10 of 191
Most frequent other events
EventArm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCG
PollakiuriaRenal and urinary disorders2/168/261/177/10
Influenza like illnessGeneral disorders0/161/260/175/10
HaematuriaRenal and urinary disorders4/1611/264/175/10
FatigueGeneral disorders3/169/263/174/10
Alanine aminotransferase increasedInvestigations1/162/264/174/10
Aspartate aminotransferase increasedInvestigations0/161/265/174/10
Blood creatinine increasedInvestigations0/161/260/174/10
DysuriaRenal and urinary disorders0/1610/261/174/10
Micturition urgencyRenal and urinary disorders0/167/260/174/10
Urinary tract infectionInfections and infestations1/169/262/173/10

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCGTotal
Mean61.8 ± 11.169.0 ± 9.469.1 ± 12.369.9 ± 16.467.5 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCGTotal
Female245112
Male142212957
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCGTotal
Hispanic or Latino02316
Not Hispanic or Latino11238951
Unknown or Not Reported516012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: NivolumabArm B: Nivolumab Plus Intravesical BCGArm C: Nivolumab Plus BMS-986205Arm D: Nivolumab Plus BMS-986205 Plus Intravesical BCGTotal
White1326171066
Asian30003
09

Study locations

88 sites
  • Local Institution - 0044
    Los Angeles, California 90033, United States
  • Local Institution - 0081
    Riverside, California 92505, United States
  • Local Institution - 0087
    San Francisco, California 94158, United States
  • Local Institution - 0125
    Tampa, Florida 33612, United States
  • Local Institution - 0056
    Hapeville, Georgia 30354, United States
  • Local Institution - 0023
    New Lenox, Illinois 60451, United States
  • Wichita Urology Group
    Wichita, Kansas 67226, United States
  • Local Institution - 0001
    Baltimore, Maryland 21287, United States
  • Local Institution - 0077
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0032
    Minneapolis, Minnesota 55455, United States
  • Local Institution - 0040
    Omaha, Nebraska 68114, United States
  • Local Institution - 0144
    New Brunswick, New Jersey 08903, United States
  • Deleware Valley Urology, LLC
    Voorhees, New Jersey 08043, United States
  • Local Institution - 0051
    New York, New York 10016, United States
  • Local Institution - 0058
    Columbus, Ohio 43212, United States
  • Local Institution - 0036
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Local Institution - 0049
    Charleston, South Carolina 29425, United States
  • Local Institution - 0002
    Myrtle Beach, South Carolina 29572, United States
  • Local Institution - 0057
    Chattanooga, Tennessee 37403, United States
  • Urology Clinics Of North Texas, Pa
    Dallas, Texas 75231, United States
  • Local Institution - 0048
    Houston, Texas 77030, United States
  • Local Institution - 0140
    Houston, Texas 77030, United States
  • Local Institution - 0047
    Lubbock, Texas 79415, United States
  • Urology San Antonio Research, Pa
    San Antonio, Texas 78229, United States
  • Local Institution - 0141
    Seattle, Washington 98195, United States
  • Local Institution - 0068
    Capital Federal, Buenos Aires 1426, Argentina
  • Local Institution - 0065
    Capital Federal, Distrito Federal C1280AEB, Argentina
  • Local Institution - 0089
    Ciudad Autonoma Buenos Aires, Distrito Federal 1118, Argentina
  • Local Institution
    Viedma, RIO Negro 8500, Argentina
  • Instituto Oncologico De Cordoba
    Cordoba, 5000, Argentina
  • Local Institution - 0137
    Mendoza, 5500, Argentina
  • Local Institution - 0146
    Camperdown, New South Wales 2050, Australia
  • Local Institution - 0148
    St Leonards, New South Wales 2065, Australia
  • Local Institution - 0072
    Fortaleza, Ceara 60135-237, Brazil
  • Local Institution - 0151
    Curitiba, Parana 80810050, Brazil
  • Local Institution - 0073
    Porto Alegre, RIO Grande DO SUL 91350-200, Brazil
  • Local Institution
    Itacorubi, Florianopolis, Santa Catarina 88034, Brazil
  • Local Institution - 0078
    Jau, Sao Paulo 17210-120, Brazil
  • Local Institution - 0150
    Rio de Janeiro, 20230-130, Brazil
  • Local Institution - 0074
    Sao Paulo, 01246-000, Brazil
  • Local Institution - 0143
    North York, Ontario M2K 1E1, Canada
  • Local Institution - 0086
    Toronto, Ontario M4N 3M5, Canada
  • Local Institution - 0084
    Toronto, Ontario M5G 2M9, Canada
  • Local Institution - 0046
    Quebec City, Quebec G1J 1Z4, Canada
  • Local Institution - 0154
    Santiago, Metropolitana 8420383, Chile
  • Local Institution - 0069
    Santiago, Metropolitana, Chile
  • Local Institution - 0128
    Beijing, Beijing 100021, China
  • Local Institution - 0131
    Beijing, Beijing 100034, China
  • Local Institution - 0116
    Beijing, Beijing 100142, China
  • Local Institution - 0099
    Beijing, Beijing 100191, China
  • Local Institution - 0129
    Chongqing, Chongqing 400030, China
  • Local Institution - 0108
    Fuzhou, Fujian 350001, China
  • Local Institution - 0117
    Guangzhou, Guangdong 510000, China
  • Local Institution - 0102
    Nanjing, Jiangsu 210008, China
  • Local Institution - 0109
    Nan Chang, Jiangxi 330000, China
  • Local Institution - 0112
    Jinan, Shandong 250012, China
  • Local Institution - 0111
    Yantai, Shandong 264000, China
  • Local Institution - 0098
    Shanghai, Shanghai 200025, China
  • Local Institution - 0094
    Shanghai, Shanghai 200032, China
  • Local Institution - 0097
    Shanghai, Shanghai 200040, China
  • Local Institution - 0120
    Chengdu, Sichuan 610041, China
  • Local Institution - 0133
    Tianjin, Tianjin 300211, China
  • Local Institution - 0126
    Hangzhou, Zhejiang 310003, China
  • Local Institution - 0027
    Suresnes, Hauts-de-Seine 92151, France
  • Local Institution - 0028
    Angers, Maine-et-Loire 49933, France
  • Local Institution - 0031
    Bordeaux Cedex, 33076, France
  • Local Institution - 0088
    Lille, 59037, France
  • Local Institution - 0091
    Strasbourg, 67200, France
  • Local Institution - 0093
    Hong Kong, Hong Kong
  • IRCCS Istituto Nazionale Tumori Milano
    Milano, 20133, Italy
  • Instituto Nazionale Tumori Fondazione G. Pascale
    Napoli, 80131, Italy
  • Azienda Ospedaliera Universitaria Pisana
    Pisa, 56126, Italy
  • Local Institution - 0062
    Tuxtla Gutierrez, Chiapas 290838, Mexico
  • Local Institution - 0055
    Ciudad de Mexico, Distrito Federal 06100, Mexico
  • Local Institution - 0004
    Amsterdam, 1066 CX, Netherlands
  • Local Institution - 0003
    Nijmegen, 6525GA, Netherlands
  • Local Institution - 0005
    Utrecht, 3584CX, Netherlands
  • Local Institution - 0070
    Omsk, 644013, Russian Federation
  • Local Institution - 0054
    Saint-Petersburg, 194044, Russian Federation
  • Local Institution - 0153
    Saint-Petersburg, 199034, Russian Federation
  • Local Institution
    Madrid, 28041, Spain
  • Local Institution - 0033
    Malaga, 29010, Spain
  • Local Institution - 0139
    Santander, 39008, Spain
  • Local Institution - 0136
    Valencia, 46010, Spain
  • Local Institution
    Chelmsford, Essex CM1 7ET, United Kingdom
  • Local Institution
    London, Greater London N18 1QX, United Kingdom
  • Local Institution - 0013
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Local Institution - 0015
    Lancaster, LA1 4RP, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Aug 2022, 48 months.

Results were first posted in Jun 2023, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2018
First posted
May 8, 2018
StartActual
Aug 2, 2018
Primary completionActual
Aug 22, 2022
CompletionActual
Aug 24, 2022
Results first posted
Jun 1, 2023
Last update
Jun 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03519256
Responsible party
Sponsor
First posted
May 8, 2018
Start date
Aug 2, 2018
Primary completion
Aug 22, 2022
Completion
Aug 24, 2022
Results posted
Jun 1, 2023
Last update
Jun 1, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion